Prior to the AbbVie announcement, epcoritamab (GEN3013 ... The trial showed that the double-headed antibody – which targets CD3 on white blood cells and CD20 on tumour cells – was tolerable ...

AbbVie and Genmab’s would-be blockbuster epcoritamab has been recommended for conditional approval in the EU as a treatment for diffuse large B-cell lymphoma (DLBCL), an aggressive form of non ...